GPR56 contributes to the development of acute myeloid leukemia in mice

• Published in: Leukemia 2016-08, Vol.30 (8), p.1734-1741
• Main Authors: Daria, D, Kirsten, N, Muranyi, A, Mulaw, M, Ihme, S, Kechter, A, Hollnagel, M, Bullinger, L, Döhner, K, Döhner, H, Feuring-Buske, M, Buske, C
• Format: Article
• Language: English
• Subjects: 13/100; 38/77; 42; 631/45/612/194; 631/67/1990/283/1897; 631/67/395; 631/67/68; 692/308; Acute myeloid leukemia; Animals; Antibodies; Anticancer properties; Cancer Research; Carcinogenesis; Clinical trials; Cloning; Coupling (molecular); Critical Care Medicine; Dosage and administration; Female; G protein-coupled receptors; G proteins; Genes; Hematology; Heterografts; Homeodomain Proteins - physiology; Humans; Intensive; Internal Medicine; Intracellular signalling; Leukemia; Leukemia, Myeloid, Acute - etiology; Leukemogenesis; Male; Medical prognosis; Medical research; Medicine; Medicine & Public Health; Mice; Mutation; Myeloid Ecotropic Viral Integration Site 1 Protein; Neoplasm Proteins - physiology; Oncology; original-article; Patients; Phenotypes; Proteins; Receptors; Receptors, G-Protein-Coupled - deficiency; Receptors, G-Protein-Coupled - genetics; Receptors, G-Protein-Coupled - physiology; Stem cell transplantation; Stem cells; Viral antibodies
• ISSN: 0887-6924; 1476-5551
• DOI: 10.1038/leu.2016.76

The G protein-coupled receptor 56 (GPR56) was identified as part of the molecular signature of functionally validated leukemic stem cells isolated from patients with acute myeloid leukemia (AML). This report now demonstrates particularly high expression of GPR56 in patients with mutant NPM1 and FLT3-length mutation and association of high GPR56 expression with inferior prognosis in a large patient cohort treated in two independent multicenter phase III trials. Functional relevance of GPR56 expression was validated in mice, in which co-expression of Gpr56 significantly accelerated HOXA9-induced leukemogenesis and vice versa knockdown of Gpr56 delayed onset of HOXA9/MEIS1-induced AML. Overexpression of Gpr56 grossly changed the molecular phenotype of Hoxa9-transduced cells affecting pathways involved in G protein-coupled receptors (GPRCs) and associated intracellular signaling. Blockage of surface GPR56 by an anti-GPR56 antibody successfully impaired engraftment of primary human AML cells. In summary, these data demonstrate that high expression of GPR56 is able to contribute to AML development and characterize the GPR56 as a potential novel target for antibody-mediated antileukemic strategies.